Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial
Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page
- Check4 days agoChange DetectedThe revision label on the page changed from v3.6.5 to v3.6.6. This reflects a software release for the site.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision: v3.6.5 is now shown in the page footer, replacing Revision: v3.6.4. This is a minor platform update and does not affect the study history content.SummaryDifference0.0%

- Check39 days agoChange DetectedThe record history shows a new revision label, v3.6.4, replacing the previous v3.6.3, reflecting an updated version of the page history.SummaryDifference0.0%

- Check61 days agoChange DetectedThe revision label in the page footer updates from v3.6.2 to v3.6.3. This reflects a minor site update without altering study data or page functionality.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page shows Revision: v3.6.2, replacing the previous v3.6.0, indicating a small site update; the study history information remains unchanged.SummaryDifference0.0%

- Check82 days agoChange DetectedVersion history shows a new revision v3.6.0 replacing v3.5.5. A note has been added stating the study is no longer looking for participants.SummaryDifference0.2%

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.